*.- Rafael Rosell : "Lo que prima son las firmas genéticas de los tumores"... Para mi este Oncologo es el Number ONE en España en Cancer de Pulmón .
*.- Esta Patente conseguida es de las que tienen Pedigri ... se refiere a la utilización del Yondelis en pacientes con determinados niveles de marcadores moleculares que puedan predecir el resultado de la quimioterapia, en particular en pacientes con bajos niveles de expresión de BRCA1.
*.- A screening method for selecting a patient suffering from cancer for a treatment with Yondelis , comprising the steps:a) isolating mRNA from a tissue sample of the patient;b) determining a gene expression level of BRCA1 in the sample;c) comparing the BRCA1 gene expression levels in the sample with a predetermined threshold level for the BRCA1 gene expression;and classifying the patient in one of 3 groups defined as "low", "normal" or high" according to the results of the comparison of the BRCA1 gene expression level with the predetermined threshold level.
*.- Prognostic Molecular Markers
Publication number: US2008293725 (A1)
Publication date: 2008-11-27
Inventor(s): ROSELL COSTA RAFAEL [ES]; TARON ROCA MIGUEL [ES]; JIMENO DONAQUE JOSE MARIA [ES]; TERCERO LOPEZ JUAN CARLOS [ES]
Applicant(s):
Classification:
- international: A61K31/495; A61P31/00; C12Q1/68; A61K31/495; A61P31/00; C12Q1/68
- European: A61K31/4995
Application number: US20050571589 20050711
Priority number(s): EP20040076997 20040709; WO2005EP07605 20050711
Abstract of US 2008293725 (A1)
The present invention relates to the use of Yondelis in patients having certain levels of molecular markers who can predict the outcome of chemotherapy, in particular in patients having low levels of BRCA1 expression.
